FDA Approves Conexxence (denosumab-bnht), a Biosimilar to Prolia

LAKE ZURICH, Ill., March 27, 2025 — Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilar Conexxence (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug…Original Article